Galectin Therapeutics Inc. (GALT) Stock

Galectin Therapeutics Inc. (GALT) is a Healthcare stock trading at $3.69 (as of 2026-08-21), with a market capitalization of $372.64M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Understand Galectin Therapeutics Inc.: how it makes money

Galectin Therapeutics develops biopharmaceutical therapies, led by belapectin (a galectin-3 inhibitor) that is in Phase III trials for liver fibrosis and related cancer indications, and it advances these candidates through clinical development rather than earning product sales (latest quarter revenue is 0.0B).

With belapectin in Phase III and no current product revenue, the company’s path to profitability is structurally dependent on clinical trial outcomes that determine whether development can move forward.

Business quality (Weak): Clinical stage biotech with belapectin in Phase III and no product revenue reported in the latest quarter, so execution against trial endpoints is the central driver of potential value creation, but it also concentrates risk.

Bull case

Efficacy signals on the primary type of clinical endpoint versus placebo: Incidence of Varices Reduction versus Placebo is 43.2% (Intent-to-Treat) and 49.3% (Per-Protocol).
Trial execution scale is measurable through enrollment: The NAVIGATE trial includes 357 patients across 14 countries, and there are defined belapectin and placebo cohorts.

Bear case

Profitability is not yet supported by product sales: Latest-quarter revenue is 0.0B, meaning operating results depend on ongoing development rather than commercial revenue.
Clinical outcome risk remains high in a Phase III setting: Key efficacy metrics are still clinical outcomes (for example, varices reduction and liver stiffness worsening), so negative or ambiguous results would directly undermine the development path.

Valuation — source: SEC EDGAR (first-party)
Price	$3.69
Market Cap	$372.64M
Price / Sales	2888.68

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$126000.00
Net Margin	-24473.0%
Revenue Growth (YoY)	7.7%
EPS Growth (YoY)	16.7%

Financial Health — source: SEC EDGAR
Altman Z-Score	-32.70 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($9.52M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Joel Lewis
Employees	15
Country	US
IPO Date	2002-09-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.